Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | 14.84 |
Low | 14.84 |
Bid | -- |
Offer | -- |
Previous close | 13.60 |
Average volume | 1.28k |
---|---|
Shares outstanding | 43.83m |
Free float | 41.36m |
P/E (TTM) | -- |
Market cap | 596.09m USD |
EPS (TTM) | -0.3829 USD |
Data delayed at least 15 minutes, as of Oct 11 2024 19:06 BST.
More ▼
Announcements
- Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft®
- Axogen Reports Inducement Grant to New Employee Under NASDAQ Listing Rule 5635(C)(4)
- Axogen, Inc. Announces New Leadership Appointments
- Axogen, Inc. Reports Second Quarter 2024 Financial Results
- Axogen, Inc. to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024
- Company Reports Inducement Grants to Non-Executive New Employee Under Nasdaq Listing Rule 5635(C)(4)
- Axogen, Inc Announces Full Launch of Avive+ Soft Tissue Matrix™
- Axogen Processing Center (APC) Celebrates its Opening with Ohio Leaders in Vandalia
- Axogen Inc. Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration (FDA) for Avance Nerve Graft®
- Axogen, Inc to Participate at Leerink Partners Healthcare Crossroads Conference
More ▼